IL23A and inflammatory bowel disease: This application of a multiomics approach allowed deeper understanding of local (gastrointestinal tissues) versus systemic (serum protein) immune responses driven by IL-23 in IBD patients and revealed that guselkumab mainly suppressed local gastrointestinal tissue inflammation by normalization of gut epithelial cell-injury responses (manuscript in preparation).